Barrett's esophagus: A historical perspective, an update on core practicalities and predictions on future evolutions of management

Journal of Gastroenterology and Hepatology (Australia)

Volumn 26, Issue SUPPL. 1, 2011, Pages 11-30

  Dent, John ^a  

^a ROYAL ADELAIDE HOSPITAL   (Australia)

Author keywords

Barrett's esophagus; Diagnosis; Endoscopic therapy; Esophageal adenocarcinoma; Surgery

Indexed keywords

ACETYLSALICYLIC ACID; ESOMEPRAZOLE;

ANTIREFLUX OPERATION; BARRETT ESOPHAGUS; CANCER EPIDEMIOLOGY; CANCER GRADING; CANCER RISK; CANCER STAGING; CHEMOPROPHYLAXIS; CHROMOENDOSCOPY; CLINICAL ASSESSMENT; CONFOCAL MICROSCOPY; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC IMAGING; DYSPLASIA; ENDOSCOPIC MUCOSAL RESECTION; ENDOSCOPIC SURGERY; ENDOSCOPIC THERAPY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGITIS; ESOPHAGUS RESECTION; GASTROESOPHAGEAL REFLUX; HEALTH CARE COST; HISTOPATHOLOGY; HUMAN; INTESTINE METAPLASIA; LOWER ESOPHAGUS SPHINCTER; MORBIDITY; PATHOGENESIS; PREDICTION; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK REDUCTION; VALIDATION STUDY;

EID: 78650794476     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2010.06535.x     Document Type: Review

References (104)

1. Dent J, Bremner CJ, Collen MJ, Haggitt RC, Spechler SJ. Working party report to the World Congresses of Gastroenterology, Sydney 1990. Barrett's oesophagus. J. Gastroenterol. Hepatol. 1991; 6: 1-22.
2. Shaheen NJ, Richter JE. Barrett's oesophagus. Lancet 2009; 373: 850-61.
3. Sharma P. Barrett's esophagus. N. Engl. J. Med. 2009; 361: 2548-56.
4. Spechler SJ, Fitzgerald RC, Prasad GA, Wang KK. History, molecular mechanisms, and endoscopic treatment of Barrett's esophagus. Gastroenterology 2010; 198: 854-69.
5. Sikkema M, De Jonge PJF, Steyerberg EW, Kuipers EJ. Risk of esophageal adenocarcinoma and mortality in patients with Barrett's esophagus: a systematic review and meta-analysis. Clin. Gastroenterol. Hepatol. 2010; 8: 235-44.
6. Shaheen NJ, Crosby MA, Bozymski EM, Sandler RS. Is there publication bias in the reporting of cancer risk in Barrett's esophagus? Gastroenterology 2000; 119: 333-8.
7. Lord RVN. Norman Barrett, "doyen of esophageal surgery". Ann. Surg. 1999; 229: 428-39.
8. Dent J. Review article: from 1906 to 2006-a century of major evolution of understanding of gastro-oesophageal reflux disease. Aliment. Pharmacol. Ther. 2006; 24: 1269-81.
9. Barrett NR. Chronic peptic ulcer of the oesophagus and "oesophagitis". Br. J. Surg. 1950; 38: 175-82.
10. Allison PR, Johnstone AS. The oesophagus lined with gastric mucous membrane. Thorax 1953; 8: 87-101.
11. Barrett NR. The lower esophagus lined by columnar epithelium. Surgery 1957; 41: 881-94.
12. Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R, Global Consensus Group. The Montréal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am. J. Gastroenterol. 2006; 101: 1900-20.
13. Takubo K, Vieth M, Aida J et al. Differences in the definitions used for esophageal and gastric diseases in different countries. Digestion 2009; 80: 248-57.
14. Shaheen NJ. Risk and reason in Barrett's esophagus. Clin. Gastroenterol. Hepatol. 2010; 8: 233-4.
15. Falk GW. Radiofrequency ablation of Barrett's esophagus, should everyone get it? Gastroenterology 2009; 136: 2399-402.
16. Harrison R, Perry I, Haddadim W et al. Detection of intestinal metaplasia in Barrett's esophagus: an observational comparator study suggests the need for a minimum of eight biopsies. Am. J. Gastroenterol. 2007; 102: 1154-61.
17. Das D, Ishaq S, Harrison R et al. Management of Barrett's esophagus in the UK: overtreated and underbiopsied but improved by the introduction of a national randomized trial. Am. J. Gastroenterol. 2008; 103: 1-11.
18. Riddell RH, Odze RD. Definition of Barrett's esophagus: time for a rethink-is intestinal metaplasia dead? Am. J. Gastroenterol. 2009; 104: 2588-4.
19. Liu W, Hahn H. Odze RD, Goyal RK. Metaplastic esophageal columnar epithelium without goblet cells shows DNA content abnormalities similar to goblet cell-containing epithelium. Am. J. Gastroenterol. 2009; 104: 816-24.
20. Takubo K, Aida J, Naomoto Y et al. Cardiac rather than intestinal-type background in endoscopic resection specimens of minute Barrett adenocarcinoma. Hum. Pathol. 2009; 40: 65-74.
21. Kelty CJ, Gough MD, Van Wyk Q, Stephenson TJ, Ackroyd R. Barrett's oesophagus: intestinal metaplasia is not essential for cancer risk. Scand. J. Gastroenterol. 2007; 42: 1271-4.
22. Lagergren J. Oesophageal cancer and gastro-oesophageal reflux: what is the relationship? Gut 2004; 53: 1064-5.
23. Sartori S, Nielson I, Indelli M, Trevisani L, Pazzi P, Grandi E. Barrett esophagus after chemotherapy with cyclophosphamide, methotrexate and 5-fluorouracil (CMF). An iatrogenic injury? Ann. Intern. Med. 1991; 114: 210-1.
24. Spechler SJ, Schimmel EM, Dalton JW, Doos W, Trier JS. Barrett's epithelium complicating lye ingestion with sparing of the distal esophagus. Gastroenterology 1981; 81: 580-3.
25. Csendes A, Braghetto I, Burdiles P, Korn O, Csendes P, Henríquez A. Very late results of esophagomyotomy for patients with achalasia: clinical, endoscopic, histologic, manometric, and acid reflux studies in 67 patients for a mean follow-up of 190 months. Ann. Surg. 2006; 243: 196-203.
26. Maley CC. Open questions in oesophageal adenocarcinogenesis. Gut 2007; 56: 897-8.
27. McElholm AR, McKnight A-J, Patterson CC et al. A population-based study of IGF axis polymorphisms and the esophageal inflammation, metaplasia, adenocarcinoma sequence. Gastroenterology 2010; 139: 204-12.
28. Huo X, Zhang HY, Zhang X et al. Acid and bile salt-induced CDX2 expression differs in esophageal squamous cells from patients with and without Barrett's esophagus. Gastroenterology 2010; 139: 194-203.
29. Chang EY, Morris CD, Seltman AK et al. The effect of antireflux surgery on esophageal carcinogenesis in patients with Barrett esophagus. Ann. Surg. 2007; 246: 11-21.
30. Lagergren J, Ye W, Lagergren P, Lu Y. The risk of esophageal adenocarcinoma after antireflux surgery. Gastroenterology 2010; 138: 1297-301.
31. Jankowski JA, Odze RD. Biomarkers in gastroenterology: between hope and hype comes histopathology. Am. J. Gastroenterol. 2009; 104: 1093-6.
32. Sharma P, Dent J, Armstrong D et al. The development and validation of an endoscopic grading system for Barrett's esophagus: the Prague C&M Criteria. Gastroenterology 2006; 131: 1392-9.
33. Lee YC, Cook MB, Bhatia S et al. Interobserver reliability in the endoscopic diagnosis and grading of Barrett's esophagus: an Asian multinational study. Endoscopy 2010; 42: 699-704.
34. Reid BJ, Blount PL, Feng Z, Levine DS. Optimizing endoscopic biopsy detection of early cancers in Barrett's high-grade dysplasia. Am. J. Gastroenterol. 2000; 95: 3089-96.
35. Pech O. Declaration of bankruptcy for four-quadrant biopsies in Barrett's esophagus? Clin. Gastroenterol. Hepatol. 2009; 7: 610-2.
36. Kariv R, Plesec TP, Goldblum JR et al. The Seattle protocol does not more reliably predict the detection of cancer at the time of esophagectomy than a less intensive surveillance protocol. Clin. Gastroenterol. Hepatol. 2009; 7: 653-8.
37. Wolfsen HC, Crook JE, Krishna M et al. Prospective, controlled tandem endoscopy study of narrow band imaging for dysplasia detection in Barrett's esophagus. Gastroenterology 2008; 135: 24-31.
38. Curvers WL, Bergman JJ. Multimodality imaging in Barrett's esophagus: looking longer, seeing better, and recognizing more. Gastroenterology 2008; 135: 297-312.
39. Li M, Anastassiades CP, Joshi B et al. Affinity peptide for targeted detection of dysplasia in Barrett's esophagus. Gastroenterology 2010; 139: 1472-80. doi: 10.1053/j.gastro.2010.07.007.
40. Pohl H, Rösch T, Vieth M et al. Miniprobe confocal laser microscopy for the detection of invisible neoplasia in patients with Barrett's oesophagus. Gut 2008; 57: 1648-53.
41. Wallace MB, Sharma P, Lightdale C et al. Preliminary accuracy and interobserver agreement for the detection of intraepithelial neoplasia in Barrett's esophagus with probe-based confocal laser endomicroscopy. Gastrointest. Endosc. 2010; 72: 19-24.
42. Pech O, Gossner L, Manner H et al. Prospective evaluation of the macroscopic types and location of early Barrett's neoplasia in 380 lesions. Endoscopy 2007; 39: 588-93.
43. May A, Gossner L, Pech O et al. Local endoscopic therapy for intraepithelial high-grade neoplasia and early adenocarcinoma in Barrett's oesophagus: acute-phase and intermediate results of a new treatment approach. Eur. J. Gastroenterol. Hepatol. 2002; 14: 1085-91.
44. Pech O, May A, Günter E, Gossner L, Ell C. The impact of endoscopic ultrasound and computed tomography on the TNM staging of early cancer in Barrett's esophagus. Am. J. Gastroenterol. 2006; 101: 2223-9.
45. Badreddine RJ, Prasad GA, Lewis JT et al. Depth of submucosal invasion does not predict lymph node metastasis and survival of patients with esophageal carcinoma. Clin. Gastroenterol. Hepatol. 2010; 8: 248-53.
46. Montgomery E, Canto MI. Management of high-grade dysplasia in patients with Barrett's esophagus. Clin. Gastroenterol. Hepatol. 2006; 4: 1434-9.
47. Vieth M. Low-grade dysplasia in Barrett's esophagus-an innocent bystander? Contra. Endoscopy 2007; 39: 647-9.
48. Alikhan M, Rex D, Khan A, Rahmani E, Cummings O, Ulbright TM. Variable pathologic interpretation of columnar lined esophagus by general pathologists in community practice. Gastrointest. Endosc. 1999; 50: 23-6.
49. Montgomery E, Goldblum JR, Greenson JK et al. Dysplasia as a predictive marker for invasive carcinoma in Barrett esophagus: a follow-up study based on 138 cases from a diagnostic variability study. Hum. Pathol. 2001; 32: 379-88.
50. Curvers WL, Ten Kate FJ, Krishnadath KK et al. Low-grade dysplasia in Barrett's esophagus: overdiagnosed and underestimated. Am. J. Gastroenterol. 2010; 105: 1523-30.
51. Zhu W, Appleman HD, Greenson JK et al. A histologically defined subset of high-grade dysplasia in Barrett mucosa in predictive of associated carcinoma. Am. J. Clin. Pathol. 2009; 132: 94-100.
52. Montgomery E. Refining diagnostic criteria for high-grade dysplasia in Barrett esophagus. Am. J. Clin. Pathol. 2009; 132: 7-9.
53. Wong A, Fitzgerald RC. Epidemiologic risk factors for Barrett's esophagus and associated adenocarcinoma. Clin. Gastroenterol. Hepatol. 2005; 3: 1-10.
54. El-Serag H. The association between obesity and GERD: a review of the epidemiological evidence. Dig. Dis. Sci. 2008; 53: 2307-12.
55. Ronkainen J, Aro P, Storskrubb T et al. Prevalence of Barrett's esophagus in the general population: an endoscopic study. Gastroenterology 2005; 129: 1826-31.
56. Zou D, He J, Ma X et al. Epidemiology of symptom-defined gastroesophageal reflux disease and reflux esophagitis: the systematic investigation of gastrointestinal diseases in China (SILC). Scand. J. Gastroenterol. Published online: 19 Oct 2010.
57. Akiyama T, Inamori M, Iida H et al. Shape of Barrett's epithelium is associated with prevalence of erosive esophagitis. World J. Gastroenterol. 2010; 16: 484-9.
58. Yamagishi H, Koike T, Ohara S et al. Clinical characteristics of gastroesophageal reflux disease in Japan. Hepatogastroenterology 2009; 56: 1032-4.
59. Peng S, Cui Y, Xiao Y et al. Prevalence of erosive esophagitis and Barrett's esophagus in the adult Chinese population. Endoscopy 2009; 41: 1011-7.
60. Tseng P, Lee Y, Chiu H et al. Prevalence and clinical characteristics of Barrett's esophagus in a Chinese general population. J. Clin. Gastroenterol. 2008; 42: 1074-9.
61. Park J, Kim J, Kim H et al. The prevalence of and risk factors for Barrett's esophagus in a Korean population. J. Clin. Gastroenterol. 2009; 43: 907-14.
62. Armstrong DA, Bennett JR, Blum AL et al. The endoscopic assessment of esophagitis-a progress report on observer agreement. Gastroenterology 1996; 111: 85-92.
63. Prasad GA, Bansal A, Sharma P, Wang KK. Predictors of profession in Barrett's esophagus: current knowledge and future directions. Am. J. Gastroenterol. 2010; 105: 1490-502.
64. Reid BJ, Li X, Galipeau PC, Vaughan TL. Barrett's oesophagus and oesophageal adenocarcinoma: time for a new synthesis. Nat. Rev. Cancer 2010; 10: 87-101.
65. Lim CH, Treanor D, Dixon MF, Axon ATR. Low-grade dysplasia in Barrett's esophagus has a high risk of progression. Endoscopy 2007; 39: 581-7.
66. Weston AP, Sharma P, Topalovski M, Richards R, Cherian R, Dixon A. Long-term follow-up of Barrett's high-grade dysplasia. Am. J. Gastroenterol. 2000; 95: 1888-93.
67. Reid BJ, Levine DS, Longton G, Blount PL, Rabinovitch PS. Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify low- and high-risk patient subsets. Am. J. Gastroenterol. 2000; 95: 1669-76.
68. Schnell TG, Sontag SJ, Chejfec G et al. Long-term nonsurgical management of Barrett's esophagus with high-grade dysplasia. Gastroenterology 2001; 120: 1607-19.
69. Overholt BF, Lightdale CJ, Wang KK et al. Photodynamic therapy with porfimer sodium for ablation of high-grade dysplasia in Barrett's esophagus: international, partially blinded, randomized phase III trial. Gastrointest. Endosc. 2005; 62: 488-98.
70. Rastogi A, Puli S, El-Serag HB, Bansal A, Wani S, Sharma P. Incidence of esophageal adenocarcinoma in patients with Barrett's esophagus and high-grade dysplasia: a meta-analysis. Gastrointest. Endosc. 2008; 67: 394-8.
71. Abu-Sneineh A, Tam W, Schoeman M et al. Effect of high-dose esomeprazole on gastric and oesophageal acid exposure and molecular markers in Barrett's oesophagus. Aliment. Pharmacol. Ther. 2010; 32: 1023-30. Published online: 15 AUG 2010 DOI: 10.1111/j.1365-2036.2010.04428.x.
72. Csendes A, Burdiles P, Braghetto I, Korn O, Díaz JC, Rojas J. Early and late results of the acid suppression and duodenal diversion operation in patients with Barrett's esophagus: analysis of 210 cases. World J. Surg. 2002; 26: 566-76.
73. Parrilla P, Martínez de Haro LF, Ortiz A, Munitiz V, Serrano A, Torres G. Barrett's esophagus without esophageal stricture does not increase the rate of failure of Nissen fundoplication. Ann. Surg. 2003; 237: 488-93.
74. Attwood SE, Lundell L, Hatlebakk JG et al. Medical or surgical management of GERD patients with Barrett's esophagus: the LOTUS Trial 3-year experience. J. Gastrointest. Surg. 2008; 1: 1646-55.
75. Rees REJ, Lao-Sirieix P, Wong A, Fitzgerald R. Treatment for Barrett's oesophagus. Cochrane Database Syst. Rev. 2010; Issue 1, Art No CD 004060 DOI: 10.1002/14651858.CD004060.pub2.
76. Islami F, Kamangar F, Boffetta P. Use of proton pump inhibitors and risk of progression of Barrett's esophagus to neoplastic lesions. Am. J. Gastroenterol. 2009; 104: 2646.
77. Shaheen NJ. Does fundoplication change the risk of esophageal cancer in the setting of GERD? Am. J. Gastroenterol. 2005; 100: 1009-11.
78. Vakil N, Shaw M, Kirby R. Clinical effectiveness of laparoscopic fundoplication in a US community. Am. J. Med. 2003; 114: 1-5.
79. Corley DA, Kerlikowske K, Verma J, Buffler P. Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis. Gastroenterology 2003; 124: 47-56.
80. Ilyas S, DeMars CJ, Buttar NS. Chemoprevention in Barrett's esophagus. J. Gastrointest. Cancer 2007; 38: 1-9.
81. Nguyen DM, Richardson P, El-Serag HB. Medications (NSAIDs, statins, proton pump inhibitors) and the risk of esophageal adenocarcinoma in patients with Barrett's esophagus. Gastroenterology 2010; 138: 2260-6.
82. Gatenby PA, Ramus JR, Caygill CP, Winslet MC, Watson A. Aspirin is not chemoprotective for Barrett's adenocarcinoma of the oesophagus in multicentre cohort. Eur. J. Cancer Prev. 2009; 18: 381-4.
83. Heath EI, Canto MI, Piantadosi S et al. Secondary chemoprevention of Barrett's esophagus with celecoxib: results of a randomized trial. J. Natl. Cancer Inst. 2007; 99: 545-57.
84. Wani S, Puli SR, Shaheen NJ et al. Am. J. Gastroenterol. 2009; 104: 502-13.
85. Sharma P, Falk GW, Sampliner R, Spechler SJ, Wang K. Management of nondysplastic Barrett's esophagus: where are we now? Am. J. Gastroenterol. 2009; 104: 805-8.
86. Fleischer DE, Overhlot BF, Sharma VK et al. Endoscopic ablation of Barrett's esophagus: a multicentre study with 2.5-year follow-up. Gastrointest. Endosc. 2008; 68: 867-76.
87. Inadomi JM, Somsouk MA, Madanick RD, Thomas JP, Shaheen NJ. A cost-utility analysis of ablative therapy for Barrett's esophagus. Gastroenterology 2009; 136: 2101-14.
88. Shaheen NJ, Sharma P, Overholt BF et al. Radiofrequency ablation in Barrett's esophagus with dysplasia. N. Engl. J. Med. 2009; 360: 2277-88.
89. Triadafilopoulos G. Blitzkrieg for Barrett's esophagus containing early neoplasia. Clin. Gastroenterol. Hepatol. 2010; 8: 7-9.
90. Behrens A, May A, Gossner L et al. Curative treatment for high-grade intraepithelial neoplasia in Barrett's esophagus. Endoscopy 2005; 37: 999-1005.
91. Pech O, Behrens A, May A et al. Long-term results and risk factor analysis for recurrence after curative endoscopic therapy in 349 patients with high-grade intraepithelial neoplasia and mucosal adenocarcinoma in Barrett's oesophagus. Gut 2008; 57: 1200-6.
92. Chennat J, Konda VJ, Ross AS et al. Complete Barrett's eradication endoscopic mucosal resection: an effective treatment modality for high-grade dysplasia and intramucosal carcinoma-an American single-center experience. Am. J. Gastroenterol. 2009; 104: 2684-92.
93. Moss A, Bourke MJ, Hourigan LF et al. Endoscopic resection for Barrett's high-grade dysplasia and early esophageal adenocarcinoma: an essential staging procedure with long-term therapeutic benefit. Am. J. Gastroenterol. 2010; 105: 1276-83.
94. Prasad GA, Wu TT, Wigle DA et al. Endoscopic and surgical treatment of mucosal (T1a) esophageal adenocarcinoma in Barrett's esophagus. Gastroenterology 2009; 137: 815-23.
95. Ell C, May A, Pech O et al. Curative endoscopic resection of early esophageal adenocarcinomas (Barrett's cancer). Gastrointest. Endosc. 2007; 65: 3-10.
96. Konda VJ, Ross AS, Ferguson MK et al. Is the risk of concomitant invasive esophageal cancer in high-grade dysplasia in Barrett's esophagus overestimated? Clin. Gastroenterol. Hepatol. 2008; 6: 159-64.
97. Lerut T, Nafteux PH, Moons J et al. Quality in the surgical treatment of cancer of the esophagus and gastroesophageal junction. Eur. J. Surg. Onccol. 2005; 31: 587-94.
98. Bergman JJ. Endoscopic resection for treatment of mucosal Barrett's cancer: time to swing the pendulum. Gastrointest. Endosc. 2007; 65: 11-3.
99. Yachimski P, Nishioka NS, Richards E, Hur C. Treatment of Barrett's esophagus with high-grade dysplasia or cancer: predictor of surgical versus endoscopic therapy. Clin. Gastroenterol. Hepatol. 2008; 6: 1206-11.
100. Barbiere JM, Lyratzopoulos G. Cost-effectiveness of endoscopic screening followed by surveillance for Barrett's Esophagus: a review. Gastroenterology 2009; 137: 1867-76.
101. El-Serag HB, Naik AD. Surveillance in Barrett's esophagus: lessons from behavioral economics. Gastroenterology 2009; 137: 763-5.
102. Lao-Sirieix P, Boussioutas A, Kadri SR et al. Non-endoscopic screening biomarkers for Barrett's oesophagus: from microarray analysis to the clinic. Gut 2009; 58: 1451-9.
103. Kadri SR, Lao-Siriex P, O'Donovan M et al. Acceptability and accuracy of a non-endoscopic screening test for Barrett's oesophagus in primary care: cohort study. BMJ 2010; 341: c4372. doi: 11.1136/bmj.c4732.
104. Rubenstein JH, Kao JY, Madanick RD et al. Association of adiponectin multimers with Barrett's oesophagus. Gut 2009; 58: 1583-9.